drugset / Trial / NCT07819591
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
Phase 2
Not yet recruiting
47 enrolled
Shaodong Hong
Akesobio · collabShanghai Yizhong Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure of platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 230 mg/m2 | Intravenous |